HRMY
Harmony Biosciences Holdings Inc

17,088
Loading...
Loading...
News
all
press releases
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Zacks·9d ago
News Placeholder
More News
News Placeholder
Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study
The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.
Stocktwits·10d ago
News Placeholder
Can Cannabis Stocks Reverse Their Prolonged Downtrend?
Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.
Zacks·2mo ago
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates
Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -12.82% and -1.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
REGN Q2 Earnings: Will Higher Dupixent Profits Fuel Growth?
Strong Dupixent profits and rising Eylea HD demand may help Regeneron offset pressure in its Q2 earnings report.
Zacks·2mo ago
News Placeholder
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.
Zacks·2mo ago
News Placeholder
5 High Earnings Yield Stocks to Tap Into Value Investing Gains
Unlock value with IAG, PAGP, HOPE, COMM and HRMY, five stocks with high earnings yields and strong growth signals.
Zacks·2mo ago
News Placeholder
Why Harmony Biosciences (HRMY) is Poised to Beat Earnings Estimates Again
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks·3mo ago

Latest HRMY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.